ReviewJournal of clinical medicine2024
Risk Stratification and Management of Intermediate-Risk Acute Pulmonary Embolism.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- GP6 polymorphisms and venous thromboembolism: a Chinese case-control study with cross-population assessment.BMC cardiovascular disorders · 2026Pooled it
- Percutaneous mechanical thrombectomy using the AcoStream thrombus aspiration system for intermediate-high-risk pulmonary embolism.Journal of thoracic disease · 2026Article
- Interventional Management of Intermediate-High-Risk Pulmonary Embolism: Current Evidence, Patient Selection and Personalised Treatment Strategies.Journal of clinical medicine · 2026Review
- Efficacy of an Automated Pulmonary Embolism (PE) Detection Algorithm on Routine Contrast-Enhanced Chest CT Imaging for Non-PE Studies.Journal of imaging informatics in medicine · 2026Article
- A study on the relationship between mMRC dyspnea scale and both risk stratification and poor prognosis in patients with acute pulmonary embolism.Frontiers in cardiovascular medicine · 2026Article
- Role of right/left ventricular diameter ratio in therapy selection for high and low intermediate‑risk pulmonary embolism in the Emergency Department.Experimental and therapeutic medicine · 2025Article
- The latest in the management of pulmonary embolism.Breathe (Sheffield, England) · 2025Review
- Limitations and enhancement opportunities for variceal rebleeding prediction model in patients with cirrhosis.World journal of gastroenterology · 2025Article
- Development of the Pulmonary Embolism Progression (PEP) score for predicting short-term clinical deterioration in intermediate-risk pulmonary embolism: a single-center retrospective study.Journal of thrombosis and thrombolysis · 2025Article
- Risk Factors for Short and Long-Term Mortality in Acute Pulmonary Thromboembolism: A Retrospective Study.International journal of general medicine · 2025Article
- Research progress in interventional therapy for acute intermediate-high-risk and high-risk pulmonary embolism.Journal of thoracic disease · 2024Review
- Mortality rate and factors associated with in-hospital mortality in patients hospitalized with pulmonary embolism in Germany.Journal of thrombosis and thrombolysis · 2024Article
- Imaging and Biomarkers: The Assesment of Pulmonary Embolism Risk and Early Mortality.Medicina (Kaunas, Lithuania) · 2024Article
- Perioperative Management and Outcomes after Endovascular Mechanical Thrombectomy in Patients with Submassive (Intermediate-Risk) Pulmonary Embolism: A Retrospective Observational Cohort Study.Healthcare (Basel, Switzerland) · 2024Article
- Management of Venous and Arterial Thrombosis.Journal of clinical medicine · 2024Article
- [Diagnosis and Treatment of Pulmonary Embolism and Pulmonary Hypertension in Patients With Interstitial Lung Disease].Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary embolism (PE) is the third most common cause of cardiovascular death and necessitates prompt, accurate risk assessment at initial diagnosis to guide treatment and reduce associated mortality. Intermediate-risk PE, defined as the presence of right ventricular (RV) dysfunction in the absence of hemodynamic compromise, carries a significant risk for adverse clinical outcomes and represents a unique diagnostic challenge. While small clinical trials have evaluated advanced treatment strategies beyond standard anticoagulation, such as thrombolytic or endovascular therapy, there remains continued debate on the optimal care for this patient population. Here, we review the most recent risk stratification models, highlighting differences between prediction scores and their limitations, and discuss the utility of serologic biomarkers and imaging modalities to detect right ventricular dysfunction. Additionally, we examine current treatment recommendations including anticoagulation strategies, use of thrombolytics at full and reduced doses, and utilization of invasive treatment options. Current knowledge gaps and ongoing studies are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.